Showing 6311-6320 of 8473 results for "".
- Dermatologists Need More Info About Cannabinoidshttps://practicaldermatology.com/news/dermatologists-need-more-info-about-cannabinoids/2457549/Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned about th
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Candela, VBF Provide Laser Treatments to Families Including a Special Toddlerhttps://practicaldermatology.com/news/candela-vbf-provide-laser-treatments-to-families-including-a-special-toddler/2457498/
- Case Study: Allergy Shots May Treat Severe Eczemahttps://practicaldermatology.com/news/case-study-allergy-shots-may-treat-severe-eczema/2457503/Allergy shots provided significant benefits to the eczema symptoms of a 48-year-old man, according to challenging case presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Seattle. “The man had suffered with severe eczema since chi
- Endo's CCH Improves Appearance of Cellulite in Buttockshttps://practicaldermatology.com/news/endos-cch-improves-appearance-of-cellulite-in-buttocks/2457516/Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment,
- AAD Releases New Melanoma Guidelineshttps://practicaldermatology.com/news/aad-releases-new-melanoma-guidelines/2457522/As National Healthy Skin Month begins, the American Academy of Dermatology’s (AAD) new melanoma guidelines shed light on risk of melanoma prognosis during pregnancy, the role of formal genetic testing in at-risk families and other aspects of care for primary cutaneous melanoma.
- Ortho Dermatologics' Altreno Now Available in the UShttps://practicaldermatology.com/news/ortho-dermatologics-altreno-now-available-in-the-us/2457526/Ortho Dermatologics launched Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. Altreno Lotion is the first and only tretinoin available in a lotion for acne. Altreno Lotion has been shown to be effective and generally well-tolerated
- Pennsylvania Passes SUNucate, Allowing Sunscreen Use and Protective Clothing at Schoolhttps://practicaldermatology.com/news/pennsylvania-passes-sunucate-allowing-sunscreen-use-and-protective-clothing-at-school/2457529/Pennsylvania became the 17th state to allow children to possess and apply sunscreen at school. Governor Tom Wolf approved HB 1228, a piece of legislation based on American Society for Dermatologic Surgery Association’s (ASDA) model bill known as SUNucate<
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel